Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H30N2 |
Molecular Weight | 334.4977 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@](CCCN(C)CCC1=CC=CC=C1)(C#N)C2=CC=CC=C2
InChI
InChIKey=DWAWDSVKAUWFHC-QHCPKHFHSA-N
InChI=1S/C23H30N2/c1-20(2)23(19-24,22-13-8-5-9-14-22)16-10-17-25(3)18-15-21-11-6-4-7-12-21/h4-9,11-14,20H,10,15-18H2,1-3H3/t23-/m0/s1
Molecular Formula | C23H30N2 |
Molecular Weight | 334.4977 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Levemopamil is a novel compound of the phenylalkylamine class of calcium channel blockers, possesses exceptionally high blood-brain barrier penetrability characteristics. It has a potent antagonistic action on serotonin 5-HT2-receptors. Activation of these receptors stimulates inositol phospholipid hydrolysis that can lead to the release of Ca2+ from intracellular stores as well as protein kinase C activation. Levemopamil thus has the potential for blocking deleterious increases of intracellular calcium arising from both intracellular stores and from the extracellular space. Levemopamil reduce both infarct size and extent of neuronal injury following permanent focal or transient global ischemia. The acute effect of bilateral clamping of carotid arteries on local cerebral blood flow was measured in the presence and absence of levemopamil in a separate group of rats. The data suggest that pretreatment with levemopamil reduces impairment in spatial behaviour and that this effect seems not related to the compound's cerebral vasodilatory action, but to direct neuronal mechanisms.
CNS Activity
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Practical synthesis of chiral emopamil left hand as a bioactive motif. | 2002 Aug 23 |
|
Gas chromatography-mass spectrometry and molecular genetic studies in families with the Conradi-Hünermann-Happle syndrome. | 2002 May |
|
Purification, characterization and catalytic properties of human sterol 8-isomerase. | 2002 Nov 1 |
|
Isolation of differentially expressed genes in NPM-ALK-positive anaplastic large cell lymphoma. | 2002 Sep |
|
Molecular, biochemical, and phenotypic analysis of a hemizygous male with a severe atypical phenotype for X-linked dominant Conradi-Hunermann-Happle syndrome and a mutation in EBP. | 2003 Jan 30 |
|
Discovery of novel neuronal voltage-dependent calcium channel blockers based on emopamil left hand as a bioactive template. | 2003 Mar 10 |
|
Molecular prenatal diagnosis in a case of an X-linked dominant chondrodysplasia punctata. | 2003 Sep |
|
Investigation of the phenylalkylamine binding site in hKv1.3 (H399T), a mutant with a reduced C-type inactivated state. | 2005 Oct |
|
Functional analysis of cholesterol biosynthesis by RNA interference. | 2007 May |
|
Reduced penetrance in a family with X-linked dominant chondrodysplasia punctata. | 2007 Sep-Oct |
|
Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity. | 2008 Dec 11 |
|
A Botrytis cinerea emopamil binding domain protein, required for full virulence, belongs to a eukaryotic superfamily which has expanded in euascomycetes. | 2008 Feb |
|
Two novel EBP mutations in Conradi-Hünermann-Happle syndrome. | 2008 Jul-Aug |
|
Genomic and biochemical approaches in the discovery of mechanisms for selective neuronal vulnerability to oxidative stress. | 2009 Feb 19 |
|
Gene expression profiling and network analysis reveals lipid and steroid metabolism to be the most favored by TNFalpha in HepG2 cells. | 2010 Feb 4 |
|
A novel X-linked multiple congenital anomaly syndrome associated with an EBP mutation. | 2010 Nov |
|
Conradi-Hünermann-Happle syndrome. | 2010 Nov 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8586975
Curator's Comment: Cats data
4 mg/kg/h for 15 min and then at 0.6 mg/kg/h
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:51:09 UTC 2023
by
admin
on
Sat Dec 16 15:51:09 UTC 2023
|
Record UNII |
TDE8767O88
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C333
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
||
|
NCI_THESAURUS |
C66885
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C81334
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
PRIMARY | |||
|
C052752
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
PRIMARY | |||
|
SUB08458MIG
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
PRIMARY | |||
|
6562
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
PRIMARY | |||
|
CHEMBL187829
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
PRIMARY | |||
|
101238-51-1
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
PRIMARY | |||
|
100000082823
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
PRIMARY | |||
|
72027
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
PRIMARY | |||
|
DTXSID00883092
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
PRIMARY | |||
|
TDE8767O88
Created by
admin on Sat Dec 16 15:51:10 UTC 2023 , Edited by admin on Sat Dec 16 15:51:10 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |